|
1
|
Bruix J and Sherman M: Practice Guidelines
Committee, American Association for the Study of Liver Diseases:
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM and Bruix J: Systematic review
of randomized trials for unresectable hepatocellular carcinoma:
Chemoembolization improves survival. Hepatology. 37:429–442. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Real MI, Montaña X, Planas R,
Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, et al:
Arterial embolisation or chemoembolisation versus symptomatic
treatment in patients with unresectable hepatocellular carcinoma: A
randomised controlled trial. Lancet. 359:1734–1739. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rammohan A, Sathyanesan J, Ramaswami S,
Lakshmanan A, Senthil-Kumar P, Srinivasan UP, Ramasamy R and
Ravichandran P: Embolization of liver tumors: Past, present and
future. World J Radiol. 4:405–412. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao S, Zhu X, Yang R and Guo J: TACE
combined with hepatic arterial infusion chemotherapy using
oxaliplatin,5-fluorouracil and folinic acid for intermediate and
advanced hepatocellular carcinomas. J Int Radiol. 21:377–383.
2012.
|
|
6
|
Gao S, Zhang PJ, Guo JH, Chen H, Xu HF,
Liu P, Yang RJ and Zhu X: Chemoembolization alone vs combined
chemoembolization and hepatic arterial infusion chemotherapy in
inoperable hepatocellular carcinoma patients. World J
Gastroenterol. 21:10443–1052. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishikawa M, Kakizawa H, Hieda M, Toyota N,
Katamura Y, Aikata H, Chayama K and Awai K: Long-term outcomes of
hepatic arterial port implantation using a coaxial microcatheter
system in 176 patients with hepatocellular carcinoma. Hiroshima J
Med Sci. 61:7–13. 2012.PubMed/NCBI
|
|
8
|
Paul SB and Sharma H: Role of
Transcatheter intra-arterial therapies for hepatocellular
carcinoma. J Clin Exp Hepatol. 4 Suppl 3:S112–S121. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Obi S, Sato S and Kawai T: current status
of hepatic arterial infusion chemotherapy. Liver Cancer. 4:188–199.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Song MJ: Hepatic artery infusion
chemotherapy for advanced hepatocellular carcinoma. World J
Gastroenterol. 21:3843–3849. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Heidelberger C, Chaudhuri NK, Danneberg P,
Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E and
Scheiner J: Fluorinated pyrimidines, a new class of
tumour-inhibitory compounds. Nature. 179:663–666. 1957. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Milano G, Etienne MC, Cassuto-Viguier E,
Thyss A, Santini J, Frenay M, Renee N, Schneider M and Demard F:
Influence of sex and age on fluorouracil clearance. J Clin Oncol.
10:1171–1175. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mueller F, Büchel B, Köberle D, Schürch S,
Pfister B, Krähenbühl S, Froehlich TK, Largiader CR and Joerger M:
Gender-specific elimination of continuous-infusional 5-fluorouracil
in patients with gastrointestinal malignancies: Results from a
prospective population pharmacokinetic study. Cancer Chemother
Pharmacol. 71:361–370. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Diasio RB and Harris BE: Clinical
pharmacology of 5-fluorouracil. Clin Pharmacokinet. 16:215–237.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Etienne MC, Lagrange JL, Dassonville O,
Fleming R, Thyss A, Renée N, Schneider M, Demard F and Milano G:
Population study of dihydropyrimidine dehydrogenase in cancer
patients. J Clin Oncol. 12:2248–2253. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu Z, Zhang R and Diasio RB:
Dihydropyrimidine dehydrogenase activity in human peripheral blood
mononuclear cells and liver: Population characteristics, newly
identified deficient patients, and clinical implication in
5-fluorouracil chemotherapy. Cancer Res. 53:5433–5438.
1993.PubMed/NCBI
|
|
17
|
Sumie S, Yamashita F, Ando E, Tanaka M,
Yano Y, Fukumori K and Sata M: Interventional radiology for
advanced hepatocellular carcinoma: Comparison of hepatic artery
infusion chemotherapy and transcatheter arterial lipiodol
chemoembolization. AJR Am J Roentgenol. 181:1327–1334. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Monden M, Sakon M, Sakata Y, Ueda Y and
Hashimura E: FAIT Research Group: 5-fluorouracil arterial infusion
+ interferon therapy for highly advanced hepatocellular carcinoma:
A multicenter, randomized, phase II study. Hepatol Res. 42:150–165.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W,
Guo RP and Shi M: Hepatic artery infusion chemotherapy using
mFOLFOX versus transarterial chemoembolization for massive
unresectable hepatocellular carcinoma: A prospective non-randomized
study. Chin J Cancer. 36:832017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chinese Society of Liver Cancer, Chinese
Anti-Cancer Association; Chinese Society of Clinical Oncology,
Chinese Anti-Cancer Association; Liver Cancer: Expert consensus on
the scheme of pathological diagnosis of primary liver cancer.
Zhonghua Gan Zang Bing Za Zhi. 19:254–256. 2011.(In Chinese).
PubMed/NCBI
|
|
21
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pugh RN, Murray-Lyon IM, Dawson JL,
Pietroni MC and Williams R: Transection of the oesophagus for
bleeding oesophageal varices. Br J Surg. 60:646–649. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Forner A, Reig ME, de Lope CR and Bruix J:
Current strategy for staging and treatment: the BCLC update and
future prospects. Semin Liver Dis. 30:61–74. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
National Cancer Institute: Common
Terminology Criteria for Adverse Events (CTCAE). NIH Publication;
pp. 0–71. 2010
|
|
25
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) Assessment for Hepatocellular Carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Seldinger SI: Catheter replacement of the
needle in percutaneous arteriography; a new technique. Acta radiol.
39:368–376. 1953. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Remaud G, Boisdron-Celle M, Morel A and
Gamelin A: Sensitive MS/MS-liquid chromatography assay for
simultaneous determination of tegafur, 5-fluorouracil and
5-fluorodihydrouracil in plasma. J Chromatogr B Analyt Technol
Biomed Life Sci. 824:153–160. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ishii H, Shimada M, Yamaguchi H and Mano
N: A simultaneous determination method for 5-fluorouracil and its
metabolites in human plasma with linear range adjusted by in-source
collision-induced dissociation using hydrophilic interaction liquid
chromatography-electrospray ionization-tandem mass spectrometry.
Biomed Chromatogr. 30:1882–1886. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peer CJ, McManus TJ, Hurwitz HI and Petros
WP: Development and utilization of a combined LC-UV and LC-MS/MS
method for the simultaneous analysis of tegafur and 5-fluorouracil
in human plasma to support a phase I clinical study of oral
UFT(R)/leucovorin. J Chromatogr B Analyt Technol Biomed Life Sci.
898:32–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Licea-Perez H, Wang S and Bowen C:
Development of a sensitive and selective LC-MS/MS method for the
determination of alpha-fluoro-beta-alanine, 5-fluorouracil and
capecitabine in human plasma. J Chromatogr B Analyt Technol Biomed
Life Sci. 877:1040–1046. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Büchel B, Rhyn P, Schürch S, Bühr C,
Amstutz U and Largiadèr CR: LC-MS/MS method for simultaneous
analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and
5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug
monitoring and toxicity prediction in cancer patients. Biomed
Chromatogr. 27:7–16. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kosovec JE, Egorin MJ, Gjurich S and
Beumer JH: Quantitation of 5-fluorouracil (5-FU) in human plasma by
liquid chromatography/electrospray ionization tandem mass
spectrometry. Rapid Commun Mass Spectrom. 22:224–230. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Carli D, Honorat M, Cohen S, Megherbi M,
Vignal B, Dumontet C, Payen L and Guitton J: Simultaneous
quantification of 5-FU, 5-FUrd, 5-FdUrd, 5-FdUMP, dUMP and TMP in
cultured cell models by LC-MS/MS. J Chromatogr B Analyt Technol
Biomed Life Sci. 877:2937–2944. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Boisdron-Celle M, Remaud G, Traore S,
Poirier AL, Gamelin L, Morel A and Gamelin E:
5-Fluorouracil-related severe toxicity: A comparison of different
methods for the pretherapeutic detection of dihydropyrimidine
dehydrogenase deficiency. Cancer Lett. 249:271–282. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Garg MB, Sevester JC, Sakoff JA and
Ackland SP: Simple liquid chromatographic method for the
determination of uracil and dihydrouracil plasma levels: a
potential pretreatment predictor of 5-fluorouracil toxicity. J
Chromatogr B Analyt Technol Biomed Life Sci. 774:223–230. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiang H, Jiang J, Hu P and Hu Y:
Measurement of endogenous uracil and dihydrouracil in plasma and
urine of normal subjects by liquid chromatography-tandem mass
spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci.
769:169–176. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jiang H, Lu J and Ji J: Circadian rhythm
of dihydrouracil/uracil ratios in biological fluids: A potential
biomarker for dihydropyrimidine dehydrogenase levels. Br J
Pharmacol. 141:616–623. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ben Fredj R, Gross E, Ben Ahmed S, Hassine
H and Saguem S: The dihydrouracil/uracil ratio in plasma, clinical
and genetic analysis for screening of dihydropyrimidine
dehydrogenase deficiency in colorectal cancer patients treated with
5-fluorouracil. Pathol Biol (Paris). 57:470–476. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gamelin E, Boisdron-Celle M, Guérin-Meyer
V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N and Robert
J: Correlation between uracil and dihydrouracil plasma ratio,
fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in
patients with advanced colorectal cancer: A potential interest for
predicting 5-FU toxicity and determining optimal 5-FU dosage. J
Clin Oncol. 17:11051999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ciccolini J, Mercier C, Evrard A, Dahan L,
Boyer JC, Duffaud F, Richard K, Blanquicett C, Milano G, Blesius A,
et al: A rapid and inexpensive method for anticipating severe
toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther
Drug Monit. 28:678–685. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Seitz JF, Cano JP, Rigault JP, Aubert C
and Carcassonne Y: Chemotherapy of extensive digestive cancers with
5-fluorouracil: Relation between the clinical response and plasma
clearance of the drug. Gastroenterol Clin Biol. 7:374–380. 1983.(In
French). PubMed/NCBI
|
|
42
|
Gamelin EC, Danquechin-Dorval EM, Dumesnil
YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH,
Gesta PH and Larra FG: Relationship between 5-fluorouracil (5-FU)
dose intensity and therapeutic response in patients with advanced
colorectal cancer receiving infusional therapy containing 5-FU.
Cancer. 77:441–451. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gamelin E, Delva R, Jacob J, Merrouche Y,
Raoul JL, Pezet D, Dorval E, Piot G, Morel A and Boisdron-Celle M:
Individual fluorouracil dose adjustment based on pharmacokinetic
follow-up compared with conventional dosage: Results of a
multicenter randomized trial of patients with metastatic colorectal
cancer. J Clin Oncol. 26:2099–2105. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Alanazi FK, Yassin AE, El-Badry M, Mowafy
HA and Alsarra IA: Validated high-performance liquid
chromatographic technique for determination of 5-fluorouracil:
Applications to stability studies and simulated colonic media. J
Chromatogr Sci. 47:558–563. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Serve KM, Yáñez JA, Remsberg CM, Davies NM
and Black ME: Development and validation of a rapid and sensitive
HPLC method for the quantification of 5-fluorocytosine and its
metabolites. Biomed Chromatogr. 24:556–561. 2010.PubMed/NCBI
|
|
46
|
Licea-Perez H, Wang S and Bowen C:
Development of a sensitive and selective LC-MS/MS method for the
determination of alpha-fluoro-beta-alanine, 5-fluorouracil and
capecitabine in human plasma. J Chromatogr B Analyt Technol Biomed
Life Sci. 877:1040–1046. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Blaschke M, Blumberg J, Wegner U,
Nischwitz M, Ramadori G and Cameron S: Measurements of 5-FU plasma
concentrations in patients with gastrointestinal cancer: 5-FU
levels reflect the 5-FU dose applied. J Cancer Ther. 3:28–36. 2012.
View Article : Google Scholar
|
|
48
|
Jianshi L: Pharmacology [M]: Tsinghua
University Press. 3:20–21. 2015.
|
|
49
|
Kaldate RR, Haregewoin A, Grier CE,
Hamilton SA and McLeod HL: Modeling the 5-fluorouracil area under
the curve versus dose relationship to develop a pharmacokinetic
dosing algorithm for colorectal cancer patients receiving FOLFOX6.
Oncologist. 17:296–302. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Machover D, Goldschmidt E, Chollet P,
Metzger G, Zittoun J, Marquet J, Vandenbulcke JM, Misset JL,
Schwarzenberg L, Fourtillan JB, et al: Treatment of advanced
colorectal and gastric adenocarcinomas with 5-fluorouracil and
high-dose folinic acid. J Clin Oncol. 4:685–696. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Raymond E, Faivre S, Chaney S, Woynarowski
J and Cvitkovic E: Cellular and molecular pharmacology of
oxaliplatin. Mol Cancer Ther. 1:227–235. 2002.PubMed/NCBI
|
|
52
|
Moraleja I, Esteban-Fernández D, Lázaro A,
Humanes B, Neumann B, Tejedor A, Mena Luz M, Jakubowski N and
Gómez-Gómez MM: Printing metal-spiked inks for LA-ICP-MS bioimaging
internal standardization: Comparison of the different nephrotoxic
behavior of cisplatin, carboplatin, and oxaliplatin. Anal Bioanal
Chem. 408:2309–2318. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
LeRoy AF, Wehling ML, Sponseller HL,
Friauf WS, Solomon RE, Dedrick RL, Litterst CL, Gram TE, Guarino AM
and Becker DA: Analysis of platinum in biological materials by
flameless atomic absorption spectrophotometry. Biochem Med.
18:184–191. 1977. View Article : Google Scholar : PubMed/NCBI
|
